Screening Saves Lives: Working Together To Promote Early Cancer Detection
Since its peak in 1991, the cancer death rate has dropped 34%, averting an estimated 4.5 million deaths due, in part, to earlier detection of the most common types of cancer.
Screening tests are critical in early detection because they can find cancer before symptoms appear, when treatment is more likely to be successful. That's why the American Cancer Society (ACS) strongly advocates for early detection and works with corporate partners to amplify this message.
For example, when the rate of cancer screening tests dropped during the pandemic, the American Cancer Society launched the Get Screened campaign with founding partner Genentech to promote screening resources and recommendations. In 2023, the campaign was renamed I Love You Get ScreenedTM, and while rates have somewhat rebounded, there are still large portions of the screening-age population that are not up to date.
Laura Makaroff
To address this ongoing issue, ACS recently introduced the cancer risk assessment tool ACS CancerRisk360TM with support from Pfizer to help people understand their risk factors, such as family history and lifestyle, and take action to address them.
Corporate partnerships that cross sectors and disciplines bring diverse expertise, resources and innovations to accelerate progress against cancer, said Laura Makaroff, DO, senior vice president of cancer prevention at the American Cancer Society.
'Cancer is a complex public health challenge that requires collaborative solutions,' Makaroff said. 'Partnerships are essential to ACS' efforts in prevention and early detection.'
Here's how the American Cancer Society has collaborated with three corporate partners to get millions of people screened for cancer.
For more than 40 years, the American Cancer Society and biotechnology company Genentech, a member of the Roche Group, have worked together to improve cancer outcomes.
After serving as a founding sponsor of the Get Screened campaign, Genentech again worked alongside ACS in 2023 on the national education campaign Cancer Screen Week. This initiative supported cancer screening efforts in Chicago's Bronzeville neighborhood and the Love Letters For Cancer Screening awareness program that focused on Black and Latina women. The organizations expanded their work together in 2024 and 2025 with cancer screening and navigation pilots in Georgia, Ohio and Oregon designed to address barriers to cancer care related to transportation, food and housing. These initiatives have led to more than 1.4 million cancer screening tests and some 18,000 cancer diagnoses.
Levi Garraway
'Screening is an integral part of the fight against cancer,' said Levi Garraway, head of global product development and chief medical officer at Roche and Genentech. 'We have worked hard to expand access to cancer screening for everyone, including populations that may encounter barriers to sufficient health care. Our commitment to provide more accessible cancer care remains strong, yet we recognize there is more work ahead as we continue to improve health outcomes for all people impacted by cancer.'
The American Cancer Society named Pfizer its 2024 Corporate Partner of the Year, reflecting the organizations' joint efforts over several years to improve access to cancer screening and quality care.
Tina Deignan
One such initiative launched last year, Change the Odds: Uniting to Improve Cancer Outcomes, is a three-year American Cancer Society effort sponsored by Pfizer that is designed to improve health outcomes in underserved communities. It aims to do this by enhancing awareness of and access to cancer screenings, clinical trial opportunities, and patient support and comprehensive navigation. Change the Odds is initially focusing on breast and prostate cancers with the potential to expand to other types.
'Breakthrough medicines can't save lives if they can't reach the patients who need them,' said Tina Deignan, commercial president of Pfizer Oncology. 'Through our longstanding efforts with the American Cancer Society, we are working to address barriers to screening and treatment so everyone impacted by cancer can receive the care they deserve.'
The American Cancer Society expanded funding for lung cancer screening in 2024 with support from Merck and other partners. Lung cancer, the second most commonly diagnosed cancer in the U.S. — and the most common cause of cancer death — disproportionately affects people with lower socioeconomic status.
Linda Kollmar
Merck is one of the partners supporting the Get Screened campaign. This effort promotes lung cancer screening in communities with historical inequities through mobile screening, community outreach and patient navigation. It aims to reach up to 10,000 additional eligible individuals.
'Our company aligns with the ACS mission to address high disparities in cancer care,' said Linda Kollmar, associate vice president of patient innovation and engagement value and implementation at Merck Research Laboratories. 'It's critical that we understand, respect and honor the life experiences of patient communities.'
Partnerships help the American Cancer Society move its mission forward by breaking down barriers for people along the cancer continuum, Makaroff said.
'These meaningful collaborations inspire the necessary action and enable critical resources to make advancements in prevention, early detection and the treatment of cancer, ultimately changing and saving more lives.'
To Learn About All Valued Partners And How Your Organization Can Become One, Visit Cancer.org/ourpartners.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
3 hours ago
- Fox News
Colorectal cancer diagnoses soar among younger adults for one key reason
Updated cancer screening guidance has reportedly caused a spike in diagnoses among younger Americans. According to two studies by the American Cancer Society (ACS), there's been a recent surge in colorectal cancer in people aged 45 to 49. ACS scientists found that after 15 years of stable colorectal cancer (CRC) trends, U.S. diagnoses of local-stage disease skyrocketed in this age group from 2019 to 2022 — including a 50% relative increase from 2021 to 2022. "It is promising news, because the uptick in cases is likely due to first-time screening in the wake of new recommendations for younger, average-risk adults to begin testing for colorectal cancer earlier," lead author Elizabeth Schafer, an associate scientist and cancer researcher at ACS, commented in a press release. In 2018, ACS lowered the recommended age for CRC screenings from 50 to 45. The United States Preventive Services Task Force (USPSTF) enforced the same guidance in 2021. In the first study, published in the Journal of the American Medical Association (JAMA), the researchers analyzed CRC diagnoses from 2004 to 2022 among adults aged 20 to 54, sorted by age, location and stage at diagnosis. Diagnoses have increased by 1.6% each year since 2004 in the 20 to 39 age group, and by more than 2% annually since 2012 in those aged 40 to 44 and 50 to 54. A 1.1% annual increase in people 45 to 49 years old accelerated to 12% per year from 2019 to 2022. The ACS confirmed the increase was driven by the detection of local-stage tumors, which increased by nearly 19% each year for colon cancer and more than 25% for rectal cancer in that timeframe. Before this period, colon cancer detection rates had been stable, and rectal cancer detection rates had been declining. Advanced-stage disease also continues to steeply increase, ACS reported, rising from 1.7% to 2.9% annually since 2004 among adults under 45 and "even more rapidly" in the past 10 years in those aged 45 to 54. These findings led to another ACS study, also published in JAMA, which found that CRC screening among U.S. adults between 45 and 49 increased by 62% from 2019 to 2023. The scientists analyzed the data of more than 50,000 individuals to compare changes in screening. They found that CRC screening, which was at 20% in 2021, jumped to 37% in 2023. Among 45- to 49-year-olds, colonoscopy screening increased by 43%, and stool-based testing increased more than five times from 2019 to 2023. Lead author Jessica Star, associate scientist at ACS in Atlanta, considers it "thrilling" to see this increase in screening among younger individuals, as it's likely linked to earlier-stage diagnoses. "However, we still have a long way to go," she said in the release. "Screening for colorectal cancer in ages 45 to 49 remains suboptimal, and has not increased equitably by both educational attainment and insurance status." Paul E. Oberstein, M.D., medical oncologist and assistant director of the Pancreatic Cancer Center at NYU Langone Perlmutter Cancer Center, said the increase in screening is "successful in detecting more cancers at an early stage where the chance of cure is very high." "This ultimately should mean that fewer people are diagnosed later in life and fewer people have advanced colon cancer," Oberstein, who was not involved in the study, told Fox News Digital. "This study reinforces the need to focus research on understanding the causes of colon cancer increases – and possible steps to reduce these cases." The rate of colon cancer in those under 45 remains "substantially lower," he noted, "so it is not clear yet if universal screening at a younger age is beneficial." Some specific patients who are younger than 45 may benefit from earlier screening, however, such as those with a family history or personal risk factors, the oncologist added. As colon cancer continues to increase in younger individuals, Oberstein recommends contacting a doctor if any concerning symptoms are noticed. Dr. Craig Eagle, chief medical officer of Guardant Health in California, added that early detection is "crucial," noting that the five-year survival rate for CRC is over 90% when the disease is caught in early stages. "[This] plummets to 13% in late stages when symptoms usually appear," Eagle, who also was not involved in the research, told Fox News Digital. "The rise in diagnoses for those in their 40s is an alarming reminder that screening must be easier and more accessible to reach the 50 million Americans who remain unscreened."
UPI
21 hours ago
- UPI
UCLA study recommends mailing stool test kits for cancer screening
A study conducted by UCLA researchers indicates sending unsolicited stool test kits to people aged 45-49 is the most effective way to increase colon cancer screening. Photo by Tamas Soki/EPA Automatically mailing a stool test kit to people's homes might be the best way to boost colon cancer screening among younger adults, a new study says. More 45- to 49-year-olds went ahead with cancer screening when they received an unsolicited stool test kit in the mail, rather than having to actively opt into screening or choose a test, researchers reported Monday in the Journal of the American Medical Association. "Removing the need for patients to actively opt into screening can lead to better outcomes, particularly when trying to engage younger, generally healthy adults who may not yet perceive themselves at risk for cancer," senior researcher Dr. Folasade May said in a news release. She's a gastroenterologist and cancer prevention researcher at the UCLA Health Jonsson Comprehensive Cancer Center. The American Cancer Society lowered its recommended age to begin colon cancer screening from 50 to 45 in 2018, and the U.S. Preventive Services Task Force followed suit in 2021, researchers said in background notes. This move has increased the detection of early-stage colon cancers among people 45 to 49, according to ACS-led studies also published Aug. 4 in JAMA. But overall rates of colon cancer screening remain low among that age group, with one recent study finding that fewer than 2% get tested, researchers said. "When national guidance recommended screening adults age 45 to 49 for colorectal cancer for the first time, it wasn't clear how to best reach and screen this newly eligible population," May said. For this study, researchers randomly assigned more than 20,500 UCLA Health system patients in that age group to one of four outreach strategies. One group was asked if they'd like to opt into screening by receiving a mailed stool test, and another if they'd opt into screening with a colonoscopy. A third group was given the choice of opting in with their choice of a stool test or colonoscopy. The final group simply was sent a stool test automatically, without asking whether they'd like to opt into screening. Sending an unsolicited stool test wound up producing the best results, with a screening rate of more than 26%, researchers found. By comparison, only 17% got screened when asked to opt in with their choice of test, 16% to opt in with a mailed stool test, and under 15% to opt in with colonoscopy. Researchers also found that 73% of those with abnormal results on their stool test followed up with a colonoscopy within six months -- a key next step in seeing whether they actually had colon cancer. Although rates were still low even for automatically mailed kits, the approach represents a simple, low-cost step forward in boosting colon cancer screening in this age group, researchers said. "Our study showed that automated outreach can get results quickly and efficiently," May said. "More than 3,800 people were screened in just six months with minimal work required from our busy doctors. That's thousands of opportunities to catch cancer early or prevent it altogether." More information The U.S. Centers for Disease Control and Prevention has more on colon cancer screening. Copyright © 2025 HealthDay. All rights reserved.
UPI
2 days ago
- UPI
Rise in colon cancer cases attributed to lower screening age
The American Cancer Society says an uptick in colon cancer cases in the 45-49 age group is a result of lowered screening ages leading to earlier detection. Photo by Adobe Stock/HealthDay There's been a steep increase in colon cancer cases among adults 45 to 49 in recent years, and that's a good thing, experts say. This upsurge means that more colon cancers are being caught at an earlier, more treatable stage, thanks to a decision to lower the screening age from 50 to 45, researchers argue in a pair of new studies from the American Cancer Society. "It is promising news because the uptick of cases is likely due to first-time screening in the wake of new recommendations for younger average-risk adults to begin testing for colorectal cancer earlier," researcher Elizabeth Schaefer, an associate scientist of surveillance and health equity science with the ACS, said in a news release. The ACS lowered its recommended age to begin colon cancer screening from 50 to 45 in 2018, and the U.S. Preventive Services Task Force followed suit in 2021, researchers said in background notes. To see whether this made a difference, researchers analyzed surveillance data on colon cancer kept by the National Cancer Institute. Results show that colon cancer diagnoses accelerated to 12% per year in people 45 to 49 between 2019 and 2022, following the change in screening recommendations, one of the studies found. That's up from an average annual increase of 1% between 2004 to 2019 among that age group, researchers said. Similarly, there was an average annual increase under 2% for adults 20 to 39, 2% among those 40 to 44 and nearly 3% among those 50 to 54. The increase in colon cancer cases for the 45-to-49 group was driven by a steep rise in the detection of early-stage colon cancers, results show. Since the screening age was lowered, nearly 19% more localized colon cancers and 25% more localized rectal cancers were diagnosed each year in that age group, researchers said. These cancers have not had a chance to spread to other parts of the body and usually cause no symptoms. American Cancer Society researchers also found that colon cancer screening among adults 45 to 49 increased by 62% between 2019 and 2023, according to findings from the second study. In that study, researchers analyzed data on colon cancer screening gathered by the National Health Interview Survey, a regular poll taken by the U.S. Centers for Disease Control and Prevention. Results showed that stool-based colon cancer testing increased more than fivefold among 45- to 49-year-olds between 2019 and 2023, and colonoscopies increased by 43%. "It's not only thrilling to see the increase in colorectal cancer screening among younger adults, but also how it likely ties into rises in earlier stage diagnosis as noted in the other ACS-led paper," researcher Jessica Star said in a news release. She's an associate scientist of cancer risk factors and screening surveillance research at the American Cancer Society. Dr. David Rivadeneira, director of the Northwell Health Cancer Institute at Huntington Hospital on Long Island, N.Y., and a colorectal cancer specialist, agrees with the researchers' take on their data. "I think both studies basically show that the screening recommendations are having a significant positive impact, meaning it's doing what it's supposed to do," Rivadeneira, who was not involved in the research, said in a news release. "It's supposed to pick up early cancers, and that's one of the good things about these two studies, that it looks like the vast majority of these cancers are in early stage, which is good because early-stage colon cancer is extremely curative," he said. The recommendation to have a colonscopy at age 45 is affecting survival in these patients, he continued. "Imagine if these patients were not screened at 45 and they have a cancer at this age. They wait till 50. That's five years down the road," Rivadeneira said. "Many of these patients would have distant metastatic or far advanced cancer where the cure rates are not so good." The two new studies were published Aug. 4 in the Journal of the American Medical Association. More information The U.S. Centers for Disease Control and Prevention has more on colon cancer screening. Copyright © 2025 HealthDay. All rights reserved.
